Calyxo, Inc.

Innovative technology for the treatment of kidney stones.

03/27/2026

🎉 Congratulations to Stephen Kappa, M.D., M.B.A. and the current president of The Urology Group on treating his 50th patient with the !

This marks a major achievement for kidney stone patients and the future of .

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/25/2026

3️⃣5️⃣0️⃣ cases! What an incredible achievement for Michael McDonald, M.D. Congratulations on completing 350 cases with the first- and second-generation CVAC System!

Thank you for your continued commitment to advancing innovation in and improving patient care. 🙌

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/24/2026

🔥300 cases! That’s 300 reasons to celebrate this milestone!

Congratulations to Daniel Hoffman, M.D. and his team on this major milestone.

Thank you for your continued commitment to advancing innovation in and improving patient care. 🙌

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/17/2026

New data presented at collectively differentiate the CVAC System as a unique, high-performance aspiration system that delivers superior stone clearance¹⁻⁵, greater procedural efficiency³, and significant reductions in long-term clinical and economic burden¹⁻².

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://calyxoinc.com/calyxo-news/six-new-eau-2026-abstracts-show-cvac-system-delivers-consistently-low-residual-stone-volume-greater-procedural-efficiency-and-reduced-downstream-clinical-and-economic-burden/

Learn more about the : https://calyxoinc.com

Safety Info: https://calyxoinc.com/isi

References:
1 Johnson B. Residual Stone Volume, Rather Than Stone-Free Status, Predicts Downstream Healthcare Utilization After Ureteroscopy: Secondary Analysis of the ASPIRE Trial. EAU 2026 Conference Presentation, March 2026. Head-to-Head Randomized Controlled Trial Comparing CVAC System Outcomes vs. Standard URS.
2 Matlaga B, Johnson B. Health-Economic Implications of the SURE Procedure in Kidney Stone Removal: A Claims Data Analysis Based on Two-Year Results of the ASPIRE Study. EAU 2026 Conference Presentation, March 2026. Head-to-Head Randomized Controlled Trial Comparing CVAC System Outcomes vs. Standard URS.
3 Winoker JS, Lee H, Jaekel D. Simulated Kidney Study of CVAC 2.0 vs. FANS: Fragment Clearance and Surgeon Workload. EAU 2026 Conference Presentation, March 2026. Preclinical study comparing CVAC System aspiration efficacy and efficiency vs. flexible and navigable sheaths.
4Pathak N. Reproducible Stone Evacuation with CVAC Technology: Pooled Analyses of the ASPIRE and CLEARANCE Trials. EAU 2026 Conference Presentation, March 2026. Pooled analysis of results from a prospective single-centre trial using the second-generation CVAC System and the ASPIRE RCT.
5 Cabo J, Amenyogbe A. Multicenter Comparison of Stone Clearance with CVAC Aspiration Ureteroscope and Flexible and Navigable Ureteral Access Sheaths. EAU 2026 Conference Presentation, March 2026. Prospective, multicenter real-world study comparing efficacy of the second-generation CVAC System and a flexible and navigable sheath.

03/16/2026

🎊 Huge congratulations to Brandon Mudd, M.D. of The Urology Group in Cincinnati, OH on completing his 25th case and achieving a remarkable 99% stone clearance! This result is a testament to the power of innovation in .

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/13/2026

Celebrating 50 cases. Let’s go! 🔥

Congratulations to Ryan Flynn, M.D. of The Urology Group in Norwood, OH on achieving this milestone.

An achievement like this doesn't happen alone. Thank you to the entire team at The Urology Group in Norwood who supported these cases!

Together, you are bringing cutting-edge technology to improve the lives of patients with kidney stones.

Learn more about Calyxo: https://lnkd.in/gGX4EyAK

Safety Info: https://calyxoinc.com/isi/

03/11/2026

🎉 We’re proud to celebrate a major achievement with Spencer Hiller, M.D., and his team at AdventHealth Medical Group Urology on completing 150 cases!

Thank you for your continued commitment to advancing innovation in and improving patient care. 🙌

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/10/2026

🎉 Congratulations to Michael Fountain, D.O. of AdventHealth Medical Group Urology at Waterman on completing the first cases in Tavares, FL!

In these two inaugural cases, he treated an average 17 mm stone burden located in the renal pelvis and lower pole, achieving 100% stone clearance. 👏

“CVAC is mandatory for future ureteroscopy cases,” shared Michael Fountain, D.O., reinforcing the impact of this cutting-edge technology in kidney stone care and in .

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

03/04/2026

🏅 We’re thrilled to announce that Julio Chong, M.D. of Colorado Urology has completed the first case at Intermountain Health Colorado.

A special thank you to Dr. Chong, Cristel Collins, and her team at IHC Good Samaritan for their partnership in expanding access to innovative kidney stone care for patients.

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

02/27/2026

🎉50 cases!

Congratulations to Daniel Robertshaw. M.D. of The Urology Group, Cincinnati, OH on completing his 50th CVAC System case! Thank you for your continued commitment to advancing innovation in and improving patient care.

Learn more about Calyxo: https://calyxoinc.com/calyxo-cvac-system/

Safety Info: https://calyxoinc.com/isi/

02/26/2026

New evidence reinforces a new, patient-centered standard for assessing efficacy of stone removal procedures. The Journal of Endourology recently published results from the CLEARANCE study and ASPIRE randomized controlled trial evaluating the CVAC System.

Key findings include:
• 96% mean stone clearance and very low residual stone volume (14.1 mm³)(1)
• 73% reduction in unplanned healthcare events* compared with standard ureteroscopy(2)
• Residual stone volume, not stone-free rate, was a predictor of long-term outcomes

These findings reinforce the importance of minimizing residual stone burden to improve meaningful, long-term patient outcomes.

Read the full release: https://calyxoinc.com/calyxo-news/cvac-system-reduces-residual-stone-volume-unplanned-health-events/

*ED visits, hospitalizations, and retreatments likely due to residual stones at the end of the procedure

References:
1 Eisner BH, et al. J Endourology. 2026.
2.Matlaga BR, et al. J Endourology. 2026.

Learn more about the : https://calyxoinc.com

Safety Info: https://calyxoinc.com/isi

02/25/2026

🌟What an achievement!

Congratulations to Center For Urology in Rochester, NY on collectively completing 600 procedures.

This milestone was made possible by these five physicians, their partners, and the entire Center of Urology team:
Alexander Cranwell, M.D.
Sameer Farooq, M.D.
Anees Fazili, M.D.
Matthew Truong, M.D.
Patrick Vecellio, M.D.

🚀 Thank you for your continued commitment to advancing innovation in and improving patient care.

Learn more about the at: https://calyxoinc.com

Safety Info: https://calyxoinc.com/isi

Address

4473 Willow Road, Suite 100
Pleasanton, CA
94588

Website

http://calyxoinc.com/

Alerts

Be the first to know and let us send you an email when Calyxo, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Calyxo, Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Pleasanton?